Are There Any Challenges in Targeting Degradation Pathways?
While targeting degradation pathways offers therapeutic potential, there are significant challenges. One major issue is the selectivity of these therapies. Inhibiting protein degradation can affect both cancerous and normal cells, leading to adverse side effects. Additionally, cancer cells may develop resistance to these therapies through compensatory mechanisms or mutations.
